The Medicines and Healthcare products Regulatory Agency (MHRA) has published Drug Safety Update for July 2010 (PDF).
This issue contains drug safety advice relating to the risk of accidental overdose with intravenous paracetamol (Perfalgan®). While this product is not likely to be widely used in primary care, clinicians should be aware of the risks and take precautions if prescribing this item.
This issue also informs readers that patient information about the Yellow Card Scheme is now available in 11 languages other than English.
The Stop Press section contains a reminder that orciprenaline sulphate (Alupent®) will be withdrawn at the end of September 2010. A recent review found that this product to be less effective and associated with a higher incidence of side effects when compared to more selective beta2-agonists.
Action: Clinicians will find this publication to be a useful review of current issues in drug safety.
|« STI rates among users of ED drugs||Influenza immunisation programme 2010/11 amendment »|